Home › Targets › HTR1F
Radioligand therapy target profile

HTR1F: IHC Expression in Cancer and Radioligand Target Profile

5-hydroxytryptamine receptor 1F · Ensembl ENSG00000179097 · Data updated 2026-11-01

HTR1F, 5-hydroxytryptamine receptor 1F, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, HTR1F staining is highest in skin cancer (90% of samples positive), head and neck cancer (75% of samples positive) and cervical cancer (82% of samples positive). Evidence on whether HTR1F internalizes is mixed. Clinical status: FDA-approved drug (any modality).

Is HTR1F the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.

Analyze HTR1F free
LocalizationCell-Surface
Top cancer (IHC)Skin Cancer
InternalizationUncertain
Clinical stageFDA-approved drug (any modality)
Active trialsSee ClinicalTrials.gov
Cancer association (Open Targets)0.39

Is HTR1F a good radioligand therapy target?

Scored against the six criteria that decide whether a protein can become a radioligand therapy:

HTR1F IHC staining by cancer type

Protein expression of HTR1F across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.

Cancer typeIHC scoreLevel% positive
Skin Cancer0.80High90%
Head and Neck Cancer0.58High75%
Cervical Cancer0.55High82%
Bladder Cancer0.52High91%
Testicular Cancer0.47Medium100%
Colorectal Cancer0.42Medium91%
Gastric Cancer0.33Medium73%
Lung Cancer0.33Medium46%
Ovarian Cancer0.31Medium58%
Neuroendocrine Tumors0.25Medium75%
Liver Cancer0.24Medium55%
Breast Cancer0.22Medium67%
Thyroid Cancer0.22Medium67%
Pancreatic Cancer0.22Medium67%
Prostate Cancer0.22Medium67%
Melanoma0.14Low33%
Endometrial Cancer0.12Low27%
Kidney Cancer0.08Low25%
Glioma0.06Low18%
Lymphoma0.03Low8%

Is HTR1F internalized?

Uncertain. Insufficient literature found.

HTR1F clinical trials

FDA-approved drug (any modality). Nuclens hasn't indexed trials for HTR1F yet. Search ClinicalTrials.gov for HTR1F trials.

HTR1F normal tissue expression

Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See HTR1F in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.

HTR1F gene essentiality (DepMap)

CRISPR knockout effect across 1232 cancer cell lines: -0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.

Related skin cancer radioligand targets

EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · B7-H3 (CD276) · HER2 (ERBB2) · ITGAV · ITGB6

See all radioligand therapy targets in skin cancer.

See how HTR1F ranks against 15,000 targets for your indication.

Analyze HTR1F free

Data sources

Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.

Is HTR1F the right target for your program? · 5 free analyses, no card Analyze HTR1F free